Agius 2020.

Study characteristics
Methods	cRCT (stepped‐wedge) Unit of randomization: clusters of villages ICC: 0.15 Trial duration: approximately 15 months
Participants	Adults or children living in malaria‐endemic regions High‐risk population (forest workers) Endemic region for P vivax Participants not screened for hypnozoites
Interventions	Topical repellent: 12% N, N‐diethylbenzamide cream Controls: no intervention Co‐interventions: LLINs Treatment arms: since this was a stepped wedge trial, all clusters moved from control to intervention. There were 14 clusters (116 villages, approx. 31,016 people)
Outcomes	Malaria prevalence Incidence of recorded adverse events (including skin irritation, local pain, eye irritation, irritation of upper airways, nausea, vomiting, headaches, dizziness or confusion, allergic or anaphylactic reactions, and systemic toxicity) Adherence to regular usage of the intervention (defined based on recommendations provided by researchers to participants of individual trials)
Notes	Malaria case incidence is mentioned as an outcome in the paper, but not reported Carried out in Myanmar Funded by: Three Millennium Development Goal, Australian Research Council, Australian Centre for Research Excellence in Malaria Elimination